InflaRx (IFRXN) AI Stock Analysis

InflaRx

(BMV:IFRXN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageVery low leverage reduces refinancing pressure and preserves financial flexibility relative to a more debt-dependent biotech. Although it does not eliminate funding needs, the limited debt burden should reduce interest-related strain and leave more strategic options as the pipeline advances.

Negative Factors

Persistent Cash BurnPersistent operating and free-cash-flow deficits show that the business is not yet self-funding. Continued cash consumption can require additional capital raises, increasing financing dependence and potentially limiting the company’s ability to sustain development without external support.

InflaRx (IFRXN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 244.63M
Dividend Yield: ―
Average Volume (3M): 5
Price to Earnings (P/E): -3.0
Beta (1Y): 0.32
Revenue Growth: ―
EPS Growth: ―
Country: Mexico
Employees: 65
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

InflaRx Business Overview & Revenue Model

Company Description

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role...

InflaRx Risk Analysis

InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Our success depends on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and other intellectual property protectionQ4, 2022

2.Our manufacturing process is subject to quality control risks and related regulatory requirementsQ4, 2022

3.Failure to maintain compliance with FDA requirements and/or remain in alignment with FDA feedback may prevent or delay the development, marketing or manufacturing of vilobelimab for the treatment of critically ill COVID-19 patients and, potentially, of vilobelimab in ulcerative PGQ4, 2022

InflaRx Peers Comparison

Overall Rating

Financial Indicators

MX:IFRXN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:IFRXN and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	MX:IFRXN	Inflarx N.V.	35.00	13.00	59.09%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

InflaRx AI Stock Analysis